BC
SPHS

Boxer Capital’s Sophiris Bio, Inc. SPHS Stock Holding History

Boxer Capital’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-546,088
Closed -$786K – 28
2016
Q1 		$786K Sell
546,088
-453,912
-45% -$800K 0.77% 18
2015
Q4 		$1.78M Buy
+1,000,000
New +$1.48M 1.54% 11

Other funds holding SPHS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AL
Airain Ltd St. Peter Port, Guernsey $2.26B AUM 12.43% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Boxer Capital's SPHS Position: Q2 2016 in Review

Boxer Capital sold out of Sophiris Bio, Inc. (SPHS) in Q2 2016, closing a stake of 546,088 shares — an estimated $786K sold.

Boxer Capital first reported a position in SPHS in Q4 2015 and held it in 2 quarters. The position peaked at $1.78M in Q4 2015. 19 funds tracked by Wall St. Rank hold SPHS as of Q2 2016.

  • Boxer Capital reported no remaining Sophiris Bio, Inc. position as of Q2 2016 after selling out during the quarter.
  • Boxer Capital sold 546,088 Sophiris Bio, Inc. shares in Q2 2016, an estimated $786K.
  • Boxer Capital first reported a position in Sophiris Bio, Inc. in Q4 2015 and held it in 2 quarters.
  • Boxer Capital's Sophiris Bio, Inc. position peaked at $1.78M in Q4 2015.
  • 19 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2016.

Based on Boxer Capital's 13F filing for Q2 2016, filed 15 Aug 2016.